ReviewNPJ Parkinson's disease2025
Iron mishandling in the brain and periphery in Parkinson's disease.
Review in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Serum Trace-Element Profiles and Exploratory Composite Indices in Multiple System Atrophy: A Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
- Research on the imbalance of metal homeostasis and ferroptosis mechanisms in neurodegenerative diseases.Global medical genetics · 2026Article
- L-DOPA influences transferrin-dependent iron release at the blood-brain barrier.Fluids and barriers of the CNS · 2026Article
- Identification of Gene Signatures and Molecular Mechanisms for Diagnosing Parkinson's Disease and Nonalcoholic Fatty Liver Disease Using Machine Learning.Parkinson's disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The heterogeneous prodromal phase of Parkinson's disease (PD) has made identifying catalysts that drive disease progression critical for effective development of disease-modifying therapies. Recently, the role of gastrointestinal dysfunction in inflammation that drives neurodegenerative risk has gained attention as a target for intervention. However, to date, there have been no clear internal or environmental catalysts identified in the gut that drive risk for PD. Here, we review the literature on iron dysregulation in the brain, blood, and gut in PD and propose that iron dysregulation outside the brain is an important catalyst that may represent a prodromal mechanistic link in gut-first PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.